

# Intraocular Pressure—Lowering Effects of All Common

Ophthalmology

112, 1177-1185

DOI: [10.1016/j.optha.2005.01.042](https://doi.org/10.1016/j.optha.2005.01.042)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Primary Open Angle Glaucoma and Ocular Hypertension. , 0, , 197-203.		0
3	Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Current Medical Research and Opinion, 2005, 21, 1875-1883.	1.9	64
4	Comments on The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries. Current Medical Research and Opinion, 2006, 22, 1899-1902.	1.9	0
5	Comparison of Diurnal Intraocular Pressure Control by Latanoprost versus Travoprost. Clinical Drug Investigation, 2006, 26, 703-714.	2.2	16
6	Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. Current Medical Research and Opinion, 2006, 22, 1643-1649.	1.9	17
7	Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase. Experimental Eye Research, 2006, 83, 1108-1117.	2.6	53
8	A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0.005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Clinical Therapeutics, 2006, 28, 332-339.	2.5	29
9	Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy. Journal of Cataract and Refractive Surgery, 2006, 32, 1499-1502.	1.5	12
10	Prostanoids in the Therapy of Glaucoma. Cardiovascular Drug Reviews, 2006, 24, 1-10.	4.1	40
11	Changes in glaucoma treatment and achieved IOP after introduction of new glaucoma medication. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 244, 1267-1272.	1.9	8
12	Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clinical and Experimental Ophthalmology, 2006, 34, 755-764.	2.6	57
13	Complex genetics of complex traits: the case of primary open-angle glaucoma. Clinical and Experimental Ophthalmology, 2006, 34, 472-484.	2.6	71
14	Bimatoprost for glaucoma therapy: pharmacology, clinical efficacy and controversy. Expert Review of Ophthalmology, 2006, 1, 141-158.	0.6	1
15	Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. British Journal of Ophthalmology, 2007, 91, 62-68.	3.9	32
16	Fixed-combination latanoprost+timolol for the treatment of glaucoma. Expert Review of Ophthalmology, 2007, 2, 537-541.	0.6	0
17	META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS COMPARING LATANOPROST WITH BRIMONIDINE IN THE TREATMENT OF OPEN-ANGLE GLAUCOMA, OCULAR HYPERTENSION OR NORMAL-TENSION GLAUCOMA. Evidence-Based Ophthalmology, 2007, 8, 150-151.	0.0	0
18	Acupuncture for glaucoma. , 2007, , CD006030.		16
19	Intraocular Pressure—Lowering Effect of Adding Dorzolamide or Latanoprost to Timolol. Ophthalmology, 2007, 114, 40-46.	5.2	22

#	ARTICLE	IF	CITATIONS
20	Effect of Laser Trabeculoplasty on Nocturnal Intraocular Pressure in Medically Treated Glaucoma Patients. <i>Ophthalmology</i> , 2007, 114, 666-670.	5.2	59
21	Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on Circadian Intraocular Pressure. <i>Ophthalmology</i> , 2007, 114, 2244-2251.e1.	5.2	20
22	Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension. <i>Current Medical Research and Opinion</i> , 2007, 23, 2971-2983.	1.9	18
23	Phacotrabeculectomy: Assessment of outcomes and surgical improvements. <i>Journal of Cataract and Refractive Surgery</i> , 2007, 33, 1201-1208.	1.5	35
24	Atlas of Glaucoma. , 0, , .		2
25	Intraocular pressure lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides. <i>Current Medical Research and Opinion</i> , 2007, 23, 595-599.	1.9	11
26	A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. <i>Current Medical Research and Opinion</i> , 2007, 23, 601-608.	1.9	77
27	Meeting Summary. <i>European Journal of Ophthalmology</i> , 2007, 17, 28-30.	1.3	1
28	Interpretation of uniocular and binocular trials of glaucoma medications: an observational case series. <i>BMC Ophthalmology</i> , 2007, 7, 17.	1.4	14
29	Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 602-611.	2.6	21
30	Immobilization of drugs for glaucoma treatment. <i>Journal of Materials Science: Materials in Medicine</i> , 2007, 18, 2309-2317.	3.6	13
31	Predicting intraocular pressure change before initiating therapy: timolol versus latanoprost. <i>Acta Ophthalmologica</i> , 2008, 86, 415-418.	1.1	10
32	The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. <i>Eye</i> , 2008, 22, 179-183.	2.1	40
33	Effects of advanced glycation end productsâ€”inductor glyoxal and hydrogen peroxide as oxidative stress factors on rat retinal organ cultures and neuroprotection by UKâ€”14,304. <i>Journal of Neurochemistry</i> , 2008, 106, 1876-1887.	3.9	19
34	Metaâ€”analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. <i>Clinical and Experimental Ophthalmology</i> , 2008, 36, 281-289.	2.6	17
35	Additive effect of dorzolamide hydrochloride to patients taking travoprost: A retrospective study. <i>Optometry - Journal of the American Optometric Association</i> , 2008, 79, 501-504.	0.6	3
36	Brinzolamide. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 653-662.	1.8	21
37	Pharmacological Management of Primary Open-Angle Glaucoma. <i>Drugs and Aging</i> , 2008, 25, 729-759.	2.7	73

#	ARTICLE	IF	CITATIONS
38	A Panel Assessment of Glaucoma Management: Modification of Existing RAND-like Methodology for Consensus in Ophthalmology. Part I: Methodology and Design. American Journal of Ophthalmology, 2008, 145, 570-574.e11.	3.3	19
39	Meta-analysis of 24-Hour Intraocular Pressure Studies Evaluating the Efficacy of Glaucoma Medicines. Ophthalmology, 2008, 115, 1117-1122.e1.	5.2	160
40	Effects of Medications and Surgery on Intraocular Pressure Fluctuation. Survey of Ophthalmology, 2008, 53, S45-S55.	4.0	24
41	Commercially Available Prostaglandin Analogs for the Reduction of Intraocular Pressure: Similarities and Differences. Survey of Ophthalmology, 2008, 53, S69-S84.	4.0	71
42	Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review. British Journal of Ophthalmology, 2008, 92, 729-734.	3.9	29
43	Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmologica, 2008, 86, 716-726.	1.1	217
44	Effect of bimatoprost on intraocular pressure after cataract surgery. Canadian Journal of Ophthalmology, 2008, 43, 712-716.	0.7	13
45	Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema?. British Journal of Ophthalmology, 2008, 92, 916-921.	3.9	67
46	Graphical exploration of network meta-analysis data: the use of multidimensional scaling. Clinical Trials, 2008, 5, 301-307.	1.6	22
47	Efficacy and Tolerability of Prostaglandin Analogs. Journal of Glaucoma, 2008, 17, 667-673.	1.6	124
48	Cardiovascular and Respiratory Considerations With Pharmacotherapy of Glaucoma and Ocular Hypertension. Cardiology in Review, 2008, 16, 95-108.	1.4	21
49	Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension. Clinical Ophthalmology, 2008, 2, 517.	1.8	36
50	Efficacy and safety of combination therapy with latanoprost after a change in therapeutic regimen from timolol to brinzolamide in Japanese adult patients with primary open-angle glaucoma and ocular hypertension: open, non-randomized 12-week study. Clinical Ophthalmology, 2008, 2, 703.	1.8	4
51	Treatment Carryover Impacts on Effectiveness of Intraocular Pressure Lowering Agents, Estimated by a Discrete Event Simulation Model. European Journal of Ophthalmology, 2008, 18, 44-51.	1.3	7
52	Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure. Clinical Ophthalmology, 2008, 2, 545.	1.8	14
53	Ocular Hypotensive Drugs. , 2008, , 139-174.		1
54	The Effect of Pneumatic Trabeculoplasty on Intraocular Pressure: The Results of a 6-Month, Open-Label, Multicenter Study. European Journal of Ophthalmology, 2008, 18, 922-928.	1.3	1
55	Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clinical Ophthalmology, 2009, 3, 593.	1.8	8

#	ARTICLE	IF	CITATIONS
56	Efficacy of the Fixed Combinations of Bimatoprost or Latanoprost plus Timolol in Patients Uncontrolled with Prostaglandin Monotherapy: A Multicenter, Randomized, Investigator-Masked, Clinical Study. <i>European Journal of Ophthalmology</i> , 2009, 19, 66-71.	1.3	35
57	Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. <i>Clinical Ophthalmology</i> , 0, , 897.	1.8	16
58	Primary open angle glaucoma. , 2009, , 239-265.		6
59	Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. <i>Clinical Ophthalmology</i> , 2009, 3, 447.	1.8	41
60	Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: short-term, multicenter, prospective study. <i>Current Medical Research and Opinion</i> , 2009, 25, 57-63.	1.9	3
61	Bimatoprost " a review. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2759-2768.	1.8	19
62	META-ANALYSIS OF MEDICAL INTERVENTION FOR NORMAL TENSION GLAUCOMA. <i>Evidence-Based Ophthalmology</i> , 2009, 10, 202-203.	0.0	0
63	Effect of selected antihypertensives, antidiabetics, statins and diuretics on adjunctive medical treatment of glaucoma: A population based study. <i>Current Medical Research and Opinion</i> , 2009, 25, 1879-1888.	1.9	30
64	Systematic Review of Intraocular Pressure-Lowering Effects of Adjunctive Medications Added to Latanoprost. <i>Ophthalmic Research</i> , 2009, 42, 99-105.	1.9	15
65	Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. <i>British Journal of Ophthalmology</i> , 2009, 93, 316-321.	3.9	96
67	Advances in telemetric continuous intraocular pressure assessment. <i>British Journal of Ophthalmology</i> , 2009, 93, 992-996.	3.9	38
68	Evaluation of risk of falls and orthostatic hypotension in older, long-term topical beta-blocker users. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 1235-1241.	1.9	16
69	Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 1353-1360.	1.9	30
70	Pharmacotherapy of intraocular pressure " part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2859-2870.	1.8	47
71	Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. <i>Experimental Eye Research</i> , 2009, 88, 535-541.	2.6	38
72	Meta-analysis of Medical Intervention for Normal Tension Glaucoma. <i>Ophthalmology</i> , 2009, 116, 1243-1249.	5.2	66
73	Brimonidine Tartrate 0.15%, Dorzolamide Hydrochloride 2%, and Brinzolamide 1% Compared as Adjunctive Therapy to Prostaglandin Analogs. <i>Ophthalmology</i> , 2009, 116, 1719-1724.	5.2	26
74	A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 1279-1283.	5.0	75

#	ARTICLE	IF	CITATIONS
75	Discrepancy between Results and Abstract Conclusions in Industry- vs Nonindustry-funded Studies Comparing Topical Prostaglandins. <i>American Journal of Ophthalmology</i> , 2009, 147, 33-38.e2.	3.3	35
76	Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. <i>Canadian Journal of Ophthalmology</i> , 2009, 44, S7-S54.	0.7	82
78	Bimatoprost. <i>Drugs and Aging</i> , 2009, 26, 1049-1071.	2.7	20
79	Bimatoprost-Induced Calcium Signaling in Human T-Cells does not Involve Prostanoid FP or TP Receptors. <i>Current Eye Research</i> , 2009, 34, 184-195.	1.5	10
80	Fixed-Combination Brimonidine/Timolol as Adjunctive Therapy to a Prostaglandin Analog: A 3-Month, Open-Label, Replacement Study in Glaucoma Patients. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 541-544.	1.4	3
81	Wireless contact lens sensor for intraocular pressure monitoring: assessment on enucleated pig eyes. <i>Acta Ophthalmologica</i> , 2009, 87, 433-437.	1.1	257
84	A Meta-analysis of Topical Prostaglandin Analogs in the Treatment of Chronic Angle-closure Glaucoma. <i>Journal of Glaucoma</i> , 2009, 18, 652-657.	1.6	28
85	Switching within glaucoma medication class. <i>Current Opinion in Ophthalmology</i> , 2009, 20, 110-115.	2.9	5
86	Prostaglandin Efficacy and Safety Study Undertaken by Race (The PRESSURE Study). <i>Journal of Glaucoma</i> , 2010, 19, 460-467.	1.6	26
88	Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension. <i>Current Medical Research and Opinion</i> , 2010, 26, 1255-1267.	1.9	15
89	A Phase II Study on the Duration and Stability of the Intraocular Pressure-Lowering Effect and Tolerability of Tafluprost Compared With Latanoprost. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2010, 26, 97-104.	1.4	47
90	Preservatives in eyedrops: The good, the bad and the ugly. <i>Progress in Retinal and Eye Research</i> , 2010, 29, 312-334.	15.5	787
91	Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. <i>Clinical Ophthalmology</i> , 2010, 4, 741.	1.8	48
92	Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension. <i>Clinical Ophthalmology</i> , 2010, 4, 877.	1.8	5
93	Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. <i>Clinical Ophthalmology</i> , 2010, 4, 1229.	1.8	16
94	A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost. <i>Clinical Ophthalmology</i> , 2010, 4, 1433.	1.8	13
95	Bimatoprost 0.03% Versus Brimonidine 0.2% in the Prevention of Intraocular Pressure Spike Following Neodymium:Yttrium-Aluminum-Garnet Laser Posterior Capsulotomy. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2010, 26, 513-517.	1.4	8
96	Medications Used to Treat Glaucoma. , 2010, , 583-628.		4

#	ARTICLE	IF	CITATIONS
97	Systemic Side Effects of Glaucoma Medications. , 2010, , 677-688.		1
98	Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study. <i>British Journal of Ophthalmology</i> , 2010, 94, 74-79.	3.9	34
99	Meta-analysis of the Efficacy and Safety of $\beta$ -Adrenergic Agonists, $\beta$ -Adrenergic Antagonists, and Topical Carbonic Anhydrase Inhibitors With Prostaglandin Analogs. <i>JAMA Ophthalmology</i> , 2010, 128, 825.	2.4	31
100	The Intraocular Pressure-Lowering Effect of Prostaglandin Analogs Combined with Topical $\beta$ -Blocker Therapy. <i>Ophthalmology</i> , 2010, 117, 2067-2074.e6.	5.2	39
101	Diurnal and Nocturnal Effects of Brimonidine Monotherapy on Intraocular Pressure. <i>Ophthalmology</i> , 2010, 117, 2075-2079.	5.2	64
102	Contrast Sensitivity and Optical Quality of the Eye after Instillation of Timolol Maleate Gel-Forming Solution and Brinzolamide Ophthalmic Suspension. <i>Ophthalmology</i> , 2010, 117, 2080-2087.	5.2	21
103	Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension. <i>American Journal of Ophthalmology</i> , 2010, 149, 661-671.e1.	3.3	76
104	Quantifying the effect of intraocular pressure reduction on the occurrence of glaucoma. <i>Acta Ophthalmologica</i> , 2010, 88, 5-11.	1.1	22
105	A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension. <i>Acta Ophthalmologica</i> , 2010, 88, 37-43.	1.1	10
106	Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. <i>Acta Ophthalmologica</i> , 2010, 88, 12-19.	1.1	100
107	Emerging drugs for ocular hypertension. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 137-161.	2.4	36
108	Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. <i>Experimental Eye Research</i> , 2011, 93, 265-270.	2.6	46
109	Comparison of Latanoprost and Timolol in Pediatric Glaucoma: A Phase 3, 12-Week, Randomized, Double-Masked Multicenter Study. <i>Ophthalmology</i> , 2011, 118, 2014-2021.	5.2	34
110	Clinical Implications of Old and New Genes for Open-Angle Glaucoma. <i>Ophthalmology</i> , 2011, 118, 2389-2397.	5.2	34
111	Intraocular pressure and ocular hemodynamics in patients with primary open-angle glaucoma treated with the combination of morning dosing of bimatoprost and dorzolamide hydrochloride. <i>Acta Ophthalmologica</i> , 2011, 89, e57-e63.	1.1	13
112	Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. <i>Current Medical Research and Opinion</i> , 2011, 27, 1949-1958.	1.9	29
113	Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months. <i>Clinical Ophthalmology</i> , 2011, 5, 393.	1.8	1
114	Demonstration of an online tool to assist managed care formulary evidence-based decision making: meta-analysis of topical prostaglandin analog efficacy. <i>Therapeutics and Clinical Risk Management</i> , 2011, 7, 283.	2.0	3

#	ARTICLE	IF	CITATIONS
115	Systematic overview of the efficacy of nonpenetrating glaucoma surgery in the treatment of open angle glaucoma. <i>Medical Science Monitor</i> , 2011, 17, RA155-RA163.	1.1	36
116	Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension. <i>Ophthalmology and Eye Diseases</i> , 2011, 3, OED.S4253.	1.2	8
117	The Clinical Impact of 2 Different Strategies for Initiating Therapy in Patients With Ocular Hypertension. <i>Journal of Glaucoma</i> , 2011, 20, 30-36.	1.6	1
119	Ocular Hypotensive Effect of Tafluprost in Latanoprost Low-responder Cynomolgus Monkeys. <i>Journal of Glaucoma</i> , 2011, 21, 1.	1.6	6
120	Medical treatment of glaucoma: present and future. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 947-959.	4.1	25
121	Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open-angle glaucoma and ocular hypertension. <i>Statistics in Medicine</i> , 2011, 30, 2511-2535.	1.6	38
122	Effect of Elevated Intracellular cAMP Levels on Actomyosin Contraction in Bovine Trabecular Meshwork Cells. , 2011, 52, 1474.		22
123	Emerging Therapeutic Regimens for Glaucoma and Ocular Hypertension. <i>Clinical Medicine Reviews in Therapeutics</i> , 2011, 4, 1-12.	0.2	0
124	Role of fixed combinations in the management of open-angle glaucoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 91-99.	1.4	14
126	Common Genetic Determinants of Intraocular Pressure and Primary Open-Angle Glaucoma. <i>PLoS Genetics</i> , 2012, 8, e1002611.	3.5	164
127	Tafluprost in the treatment of glaucoma. <i>Expert Review of Ophthalmology</i> , 2012, 7, 401-407.	0.6	1
128	Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. <i>Current Medical Research and Opinion</i> , 2012, 28, 781-788.	1.9	7
129	Effect of Ketorolac Add-On Treatment on Intra-Ocular Pressure in Glaucoma Patients Receiving Prostaglandin Analogues. <i>Ophthalmologica</i> , 2012, 227, 205-209.	1.9	13
130	Intraocular Pressure-Lowering Effect of 0.005% Latanoprost with Two Different Dosing Regimens. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2012, 28, 524-528.	1.4	1
131	Clinical Options for the Reduction of Elevated Intraocular Pressure. <i>Ophthalmology and Eye Diseases</i> , 2012, 4, OED.S4909.	1.2	40
132	Long-term Effect of BAK-free Travoprost on Ocular Surface and Intraocular Pressure in Glaucoma Patients After Transition From Latanoprost. <i>Journal of Glaucoma</i> , 2012, 21, 60-64.	1.6	37
133	What Comparative Effectiveness Research Is Needed? A Framework for Using Guidelines and Systematic Reviews to Identify Evidence Gaps and Research Priorities. <i>Annals of Internal Medicine</i> , 2012, 156, 367.	3.9	61
134	Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma. <i>Nanomedicine</i> , 2012, 7, 1067-1083.	3.3	36



#	ARTICLE	IF	CITATIONS
136	A review of the use of latanoprost for glaucoma since its launch. Expert Opinion on Pharmacotherapy, 2012, 13, 723-745.	1.8	67
137	Meta-analysis of $\beta$ -2-adrenergic agonists versus carbonic anhydrase inhibitors as adjunctive therapy. Current Medical Research and Opinion, 2012, 28, 543-550.	1.9	4
138	Randomized Clinical Trial of the Efficacy and Safety of Preservative-free Tafluprost and Timolol in Patients With Open-Angle Glaucoma or Ocular Hypertension. American Journal of Ophthalmology, 2012, 153, 1187-1196.	3.3	40
139	Assessment of thermal dehydration using the human eye: What is the potential?. Journal of Thermal Biology, 2012, 37, 111-117.	2.5	14
140	Latanoprost 0.005% Test Formulation is as Effective as Xalatan <sup>®</sup> in Patients with Ocular Hypertension and Primary Open-Angle Glaucoma. European Journal of Ophthalmology, 2012, 22, 19-27.	1.3	15
141	The Glaucoma Guidelines of the Swedish Ophthalmological Society. Acta Ophthalmologica, 2012, 90, 1-40.	1.1	17
142	Intraocular Pressure-Lowering Combination Therapies with Prostaglandin Analogues. Drugs, 2012, 72, 1355-1371.	10.9	25
143	Intraocular Pressure-Lowering Effects of Commonly Used Fixed-Combination Drugs with Timolol: A Systematic Review and Meta-Analysis. PLoS ONE, 2012, 7, e45079.	2.5	68
144	Microbead-Induced Ocular Hypertensive Mouse Model for Screening and Testing of Aqueous Production Suppressants for Glaucoma. , 2012, 53, 3733.		65
145	A New Epidemiological Aid in Deciding Whether to Continue or Stop a Treatment. , 2012, 53, 4331.		2
146	Prostaglandin-Timolol Fixed Combinations Efficacy: Myth or Reality?. European Journal of Ophthalmology, 2012, 22, 1-4.	1.3	21
147	Latanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost-effectiveness analysis. Acta Ophthalmologica, 2012, 90, 146-154.	1.1	5
148	Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions. Current Medical Research and Opinion, 2013, 29, 1201-1209.	1.9	12
149	An adherence based cost-consequence model comparing bimatoprost 0.01% to bimatoprost 0.03%. Current Medical Research and Opinion, 2013, 29, 1191-1200.	1.9	3
150	Citation of Previous Meta-analyses on the Same Topic. Ophthalmology, 2013, 120, 1113-1119.	5.2	24
151	Effects of SofZia <sup>®</sup> -preserved travoprost and benzalkonium chloride <sup>®</sup> -preserved latanoprost on the ocular surface - a multicentre randomized single-masked study. Acta Ophthalmologica, 2013, 91, e7-e14.	1.1	44
152	A novel convergent synthesis of the potent antiglaucoma agent travoprost. Tetrahedron, 2013, 69, 1634-1648.	1.9	15
153	Therapeutic uses of prostaglandin F <sub>2</sub> analogues in ocular disease and novel synthetic strategies. Prostaglandins and Other Lipid Mediators, 2013, 104-105, 109-121.	1.9	27

#	ARTICLE	IF	CITATIONS
154	A Novel Convergent Synthesis of the Antiglaucoma PGF <sub>2</sub> Analogue Bimatoprost. Chirality, 2013, 25, 170-179.	2.6	11
155	Acupuncture for glaucoma. The Cochrane Library, 2013, , CD006030.	2.8	29
156	Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost. Japanese Journal of Ophthalmology, 2013, 57, 179-184.	1.9	40
158	Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. British Journal of Ophthalmology, 2013, 97, 196-200.	3.9	82
159	Influence of BAK-Preserved Prostaglandin Analog Treatment on the Ocular Surface Health in Patients with Newly Diagnosed Primary Open-Angle Glaucoma. BioMed Research International, 2013, 2013, 1-7.	1.9	19
160	An Evaluation of Therapeutic Noninferiority of 0.005% Latanoprost Ophthalmic Solution and Xalatan in Patients With Glaucoma or Ocular Hypertension. Journal of Glaucoma, 2013, 22, 707-712.	1.6	21
161	Comparative Phospholipid Profiles of Control and Glaucomatous Human Trabecular Meshwork. , 2013, 54, 3037.		33
162	A New Target for Glaucoma Therapy. JAMA Ophthalmology, 2013, 131, E1.	2.5	2
163	Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease. Expert Opinion on Pharmacotherapy, 2013, 14, 105-113.	1.8	11
164	Preservative-free Treatment in Glaucoma: Who, when, and why?. European Journal of Ophthalmology, 2013, 23, 518-525.	1.3	38
165	A Short-term Randomized Clinical Trial of Daily Versus Alternate Day Use of Travoprost 0.004% in the Treatment of Ocular Hypertension. Journal of Glaucoma, 2013, 22, 123-126.	1.6	2
166	Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization. Journal of Personalized Medicine, 2013, 3, 40-69.	2.5	23
167	Latanoprost Stimulates Ocular Lymphatic Drainage: An In Vivo Nanotracer Study. Translational Vision Science and Technology, 2013, 2, 3.	2.2	44
168	Level of agreement among Latin American glaucoma subspecialists on the diagnosis and treatment of glaucoma: results of an online survey. Arquivos Brasileiros De Oftalmologia, 2013, 76, 163-169.	0.5	5
169	Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes. Clinical Ophthalmology, 2013, 7, 1549.	1.8	15
170	Comparison of the efficacy and safety of bimatoprost (0.03 %) and travoprost (0.004 %) in patients with primary open angle glaucoma. Nepalese Journal of Ophthalmology, 2013, 5, 75-80.	0.2	8
171	Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Preference and Adherence, 2014, 8, 853.	1.8	17
172	Ologen Implant versus Mitomycin C for Trabeculectomy: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e85782.	2.5	59

#	ARTICLE	IF	CITATIONS
173	Meta-Analysis of Randomized Controlled Trials Comparing Latanoprost with Timolol in the Treatment of Asian Populations with Chronic Angle-Closure Glaucoma. PLoS ONE, 2014, 9, e96852.	2.5	1
174	Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension. Clinical Ophthalmology, 2014, 8, 389.	1.8	2
175	Latanoprost in the treatment of glaucoma. Clinical Ophthalmology, 2014, 8, 1967.	1.8	70
176	Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions. Clinical Ophthalmology, 2014, 8, 927.	1.8	13
177	Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma. Clinical Ophthalmology, 2014, 8, 1179.	1.8	8
178	Glaucoma management: relative value and place in therapy of available drug treatments. Therapeutic Advances in Chronic Disease, 2014, 5, 30-43.	2.5	62
179	Efficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma. Current Medical Research and Opinion, 2014, 30, 1367-1373.	1.9	3
180	Late-day intraocular pressure—lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial. BMC Ophthalmology, 2014, 14, 151.	1.4	8
181	Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients. Eye, 2014, 28, 422-429.	2.1	24
182	Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. Croatian Medical Journal, 2014, 55, 468-480.	0.7	15
183	Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma. Expert Opinion on Pharmacotherapy, 2014, 15, 2255-2262.	1.8	11
184	Activation of the Prostanoid FP Receptor Inhibits Adipogenesis Leading to Deepening of the Upper Eyelid Sulcus in Prostaglandin-Associated Periorbitopathy. , 2014, 55, 1269.		68
185	Effectiveness of Intraocular Pressure—Lowering Medication Determined by Washout. JAMA Ophthalmology, 2014, 132, 390.	2.5	23
186	Bimatoprost: a unique compound that in its nonhydrolyzed form is a prostamide and hydrolyzed form has prostaglandin receptor activity, for glaucoma and cosmetic indications. Expert Review of Ophthalmology, 2014, 9, 159-173.	0.6	1
187	OCT Evaluation of Neuroprotective Effects of Tafluprost on Retinal Injury After Intravitreal Injection of Endothelin-1 in the Rat Eye. , 2014, 55, 1040.		12
188	<i>In vivo</i> confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucoma. Acta Ophthalmologica, 2014, 92, e133-40.	1.1	35
189	Genome-wide association study and meta-analysis of intraocular pressure. Human Genetics, 2014, 133, 41-57.	3.8	93
190	Twice-Daily Brinzolamide/Brimonidine Fixed Combination versus Brinzolamide or Brimonidine in Open-Angle Glaucoma or Ocular Hypertension. Ophthalmology, 2014, 121, 2348-2355.	5.2	44

#	ARTICLE	IF	CITATIONS
191	Restoring Conjunctival Tolerance by Topical Nuclear Factor- $\kappa$ B Inhibitors Reduces Preservative-Facilitated Allergic Conjunctivitis in Mice. , 2014, 55, 6116.		32
192	Genome-wide analysis of multi-ancestry cohorts identifies new loci influencing intraocular pressure and susceptibility to glaucoma. Nature Genetics, 2014, 46, 1126-1130.	21.4	212
193	Trans-conjunctival aqueous humor outflow in glaucomatous patients treated with prostaglandin analogues: an in vivo confocal microscopy study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1469-1476.	1.9	17
194	Contralateral intraocular pressure lowering effect of prostaglandin analogues. Indian Journal of Ophthalmology, 2014, 62, 575.	1.1	12
195	Relative Efficacy and Safety of Preservative-free Latanoprost (T2345) for the Treatment of Open-Angle Glaucoma and Ocular Hypertension. Journal of Glaucoma, 2014, 23, e69-e75.	1.6	31
196	Medical interventions for treating primary angle-closure glaucoma. The Cochrane Library, 0, , .	2.8	0
197	Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study. BMC Ophthalmology, 2015, 15, 166.	1.4	21
198	The Measurement of Bulbar Hyperemia: Challenges and Pitfalls. European Journal of Ophthalmology, 2015, 25, 273-279.	1.3	20
199	Unilateral Prostaglandin-Associated Periorbitopathy. Ophthalmic Plastic and Reconstructive Surgery, 2015, 31, 373-378.	0.8	36
200	Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure. Clinical Ophthalmology, 2015, 9, 633.	1.8	17
201	Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial. PLoS ONE, 2015, 10, e0140601.	2.5	19
202	Clinical effectiveness of brinzolamide 1%&ndash;brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clinical Ophthalmology, 2015, 9, 2201.	1.8	20
203	ARHGEF12 influences the risk of glaucoma by increasing intraocular pressure. Human Molecular Genetics, 2015, 24, 2689-2699.	2.9	79
204	Management of Normal-Tension Glaucoma. , 2015, , 476-483.		1
205	Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet, The, 2015, 385, 1295-1304.	13.7	494
206	Lowering Intraocular Pressure. , 2015, , 687-694.		0
207	Author reply. Ophthalmology, 2015, 122, e36-e37.	5.2	0
208	Perioperative pharmacological management in patients with glaucoma. Archivos De La Sociedad Espanola De Oftalmologia, 2015, 90, 274-284.	0.2	1

#	ARTICLE	IF	CITATIONS
209	Aggregate Effects of Intraocular Pressure and Cup-to-Disc Ratio Genetic Variants on Glaucoma in a Multiethnic Asian Population. <i>Ophthalmology</i> , 2015, 122, 1149-1157.	5.2	28
210	Manejo farmacológico perioperatorio en pacientes con glaucoma. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2015, 90, 274-284.	0.2	3
211	Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial. <i>BMC Ophthalmology</i> , 2015, 15, 7.	1.4	5
212	The effect of flavonoids on visual function in patients with glaucoma or ocular hypertension: a systematic review and meta-analysis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2015, 253, 1841-1850.	1.9	44
213	Alpha Agonists. , 2015, , 566-576.		1
214	Beta-Blockers. , 2015, , 548-558.		1
215	Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 1759-1765.	1.8	8
216	The Suprachoroidal Route in Glaucoma Surgery. <i>Journal of Current Glaucoma Practice</i> , 2016, 10, 13-20.	0.5	32
217	The intraocular pressure-lowering properties of intravenous paracetamol. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 1283-1289.	1.8	3
218	Medical Management of Glaucoma in the 21st Century from a Canadian Perspective. <i>Journal of Ophthalmology</i> , 2016, 2016, 1-22.	1.3	70
219	Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 2085-2091.	1.8	13
220	Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost. <i>Journal of Glaucoma</i> , 2016, 25, e610-e614.	1.6	14
221	Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management. <i>Ophthalmology and Therapy</i> , 2016, 5, 47-61.	2.3	31
222	Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial. <i>Eye</i> , 2016, 30, 1343-1350.	2.1	15
223	Treatment of Glaucoma with or without Medications Lowering Intraocular Pressure: Options and Relevant General Health Issues. <i>ESASO Course Series</i> , 2016, , 52-75.	0.1	0
224	Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells. <i>Advances in Therapy</i> , 2016, 33, 1452-1459.	2.9	14
225	Medical Treatment: First-Line Agents, Monotherapy, and Combination Therapy. , 2016, , 227-242.		0
227	Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells. <i>Scientific Reports</i> , 2016, 6, 19640.	3.3	106

#	ARTICLE	IF	CITATIONS
228	Glaucoma-Intraocular Pressure Reduction. Handbook of Experimental Pharmacology, 2016, 242, 181-207.	1.8	8
229	Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity. Medicine (United States), 2016, 95, e5745.	1.0	20
230	Cyclic RGD peptides target human trabecular meshwork cells while ameliorating connective tissue growth factor-induced fibrosis. Journal of Drug Targeting, 2016, 24, 952-959.	4.4	12
231	24-h Efficacy of Glaucoma Treatment Options. Advances in Therapy, 2016, 33, 481-517.	2.9	35
232	Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 1151-1158.	1.9	14
233	Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring. Japanese Journal of Ophthalmology, 2016, 60, 27-34.	1.9	11
234	New insights into the genetics of primary open-angle glaucoma based on meta-analyses of intraocular pressure and optic disc characteristics.. Human Molecular Genetics, 2017, 26, ddw399.	2.9	120
235	Cardiovascular medication and intraocular pressure: results from the Gutenberg Health Study. British Journal of Ophthalmology, 2017, 101, 1633-1637.	3.9	19
236	Microinvasive Glaucoma Stent (MIGS) Surgery With Concomitant Phakoemulsification Cataract Extraction: Outcomes and the Learning Curve. Journal of Glaucoma, 2017, 26, 646-651.	1.6	18
237	Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial. American Journal of Ophthalmology, 2017, 175, 137-147.	3.3	98
238	Minimally invasive glaucoma surgery as primary stand-alone surgery for glaucoma. Clinical and Experimental Ophthalmology, 2017, 45, 393-400.	2.6	84
239	Achievements and Limits of Current Medical Therapy of Glaucoma. Developments in Ophthalmology, 2017, 59, 1-14.	0.1	27
240	Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 591-597.	1.4	6
241	European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation. British Journal of Ophthalmology, 2017, 101, 130-195.	3.9	216
242	Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term?. International Ophthalmology, 2017, 37, 619-626.	1.4	5
243	Additive Intraocular Pressure-Lowering Effects of Ripasudil with Glaucoma Therapeutic Agents in Rabbits and Monkeys. Journal of Ophthalmology, 2017, 2017, 1-8.	1.3	11
244	Patient Acceptance of Sustained Glaucoma Treatment Strategies. Journal of Glaucoma, 2018, 27, 328-335.	1.6	13
245	A stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for ocular drug delivery. Drug Delivery and Translational Research, 2018, 8, 484-495.	5.8	35

#	ARTICLE	IF	CITATIONS
246	Prostaglandin F2 $\pm$ Receptor Modulation Affects Eye Development in Guinea Pigs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 263-270.	2.5	9
247	Prospective study comparing Xalatan <sup>®</sup> eye drops and two similar generics as to the efficacy and safety profile. <i>European Journal of Ophthalmology</i> , 2018, 28, 378-384.	1.3	10
248	The Effects of Latanoprost With Benzalkonium Chloride Versus Travoprost With SofZia on the Ocular Surface. <i>Eye and Contact Lens</i> , 2018, 44, S93-S98.	1.6	5
249	Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. <i>Drugs</i> , 2018, 78, 39-64.	10.9	43
250	Assessing the Methodological Quality of Glaucoma Clinical Practice Guidelines and Their Recommendations on Microinvasive Glaucoma Surgery: A Systematic Review. <i>Journal of Glaucoma</i> , 2018, 27, e44-e49.	1.6	11
251	Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study. <i>Clinical Ophthalmology</i> , 2018, Volume 12, 2399-2407.	1.8	25
252	Initial intraocular pressure reduction by mono- versus multi-therapy in patients with open-angle glaucoma: results from the Glaucoma Intensive Treatment Study. <i>Acta Ophthalmologica</i> , 2018, 96, 567-572.	1.1	19
253	Effects of sustained daily latanoprost application on anterior chamber anatomy and physiology in mice. <i>Scientific Reports</i> , 2018, 8, 13088.	3.3	0
254	Diurnal and 24-h Intraocular Pressures in Glaucoma: Monitoring Strategies and Impact on Prognosis and Treatment. <i>Advances in Therapy</i> , 2018, 35, 1775-1804.	2.9	49
255	Genome-wide analyses identify 68 new loci associated with intraocular pressure and improve risk prediction for primary open-angle glaucoma. <i>Nature Genetics</i> , 2018, 50, 778-782.	21.4	214
256	Effects of brimonidine tartrate 0.1% ophthalmic solution on the pupil, refraction, and light reflex. <i>Scientific Reports</i> , 2018, 8, 9003.	3.3	10
257	The More, the Better? The Usefulness of Brimonidine as the Fourth Antiglaucoma Eye Drop. <i>Journal of Glaucoma</i> , 2018, 27, 643-646.	1.6	5
258	The effect of multiple vitrectomies and its indications on intraocular pressure. <i>BMC Ophthalmology</i> , 2019, 19, 175.	1.4	4
259	Determining Possible Shared Genetic Architecture Between Myopia and Primary Open-Angle Glaucoma. , 2019, 60, 3142.		10
260	Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or $\beta^2$ -Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 679.	3.5	11
261	Air-Puff-Induced Dynamics of Ocular Components Measured with Optical Biometry. , 2019, 60, 1979.		14
262	Glaucoma: a prescriber's guide. <i>Journal of Prescribing Practice</i> , 2019, 1, 278-282.	0.1	0
263	<p>A theory-driven qualitative study exploring issues relating to adherence to topical glaucoma medications</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 819-828.	1.8	9

#	ARTICLE	IF	CITATIONS
264	Latanoprost treatment differentially affects intraocular pressure readings obtained with three different tonometers. <i>Acta Ophthalmologica</i> , 2019, 97, e1112-e1115.	1.1	9
265	Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life. <i>Journal of Ophthalmology</i> , 2019, 2019, 1-12.	1.3	21
266	Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma. <i>American Journal of Ophthalmology</i> , 2019, 205, 91-98.	3.3	7
267	Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostaglandins for Open-Angle Glaucoma. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2019, 35, 145-160.	1.4	10
268	Current management of glaucoma. <i>Medical Journal of Australia</i> , 2019, 210, 180-187.	1.7	206
269	The Relationship Between Ambient Atmospheric Fine Particulate Matter (PM <sub>2.5</sub> ) and Glaucoma in a Large Community Cohort. , 2019, 60, 4915.		60
271	Ascorbic acid metabolites are involved in intraocular pressure control in the general population. <i>Redox Biology</i> , 2019, 20, 349-353.	9.0	31
272	Effects of caffeine on intraocular pressure are subject to tolerance: a comparative study between low and high caffeine consumers. <i>Psychopharmacology</i> , 2019, 236, 811-819.	3.1	25
273	Myocilin Gene Gln368Ter Variant Penetrance and Association With Glaucoma in Population-Based and Registry-Based Studies. <i>JAMA Ophthalmology</i> , 2019, 137, 28.	2.5	32
274	Brinzolamide-brimonidine fixed combination for the prevention of intraocular pressure elevation after phacoemulsification. <i>European Journal of Ophthalmology</i> , 2020, 30, 293-298.	1.3	4
275	Changes in intraocular pressure during reading or writing on smartphones in patients with normal-tension glaucoma. <i>British Journal of Ophthalmology</i> , 2020, 104, 623-628.	3.9	5
276	Reply to Comment on: Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase after Cataract Surgery in Eyes with Glaucoma. <i>American Journal of Ophthalmology</i> , 2020, 211, 231-232.	3.3	0
278	A review of systemic medications that may modulate the risk of glaucoma. <i>Eye</i> , 2020, 34, 12-28.	2.1	52
279	Comparison of Associations with Different Macular Inner Retinal Thickness Parameters in a Large Cohort. <i>Ophthalmology</i> , 2020, 127, 62-71.	5.2	64
280	24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients. <i>Drugs</i> , 2020, 80, 167-179.	10.9	63
281	Comment on: Effect of Topical Hypotensive Medications for Preventing Intraocular Pressure Increase After Cataract Surgery in Eyes With Glaucoma. <i>American Journal of Ophthalmology</i> , 2020, 210, 192.	3.3	0
282	10-year trends in English primary care glaucoma prescribing. <i>Eye</i> , 2020, 34, 192-196.	2.1	8
283	&lt;p>&gt;The Latest Drugs in Development That Reduce Intraocular Pressure in Ocular Hypertension and Glaucoma&lt;/p>. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 539-548.	3.2	22



#	ARTICLE	IF	CITATIONS
284	Harnessing emerging paradigms in chemical engineering to accelerate the development of pharmaceutical products. <i>Canadian Journal of Chemical Engineering</i> , 2020, 98, 2294-2300.	1.7	2
285	The Role of Chromosome X in Intraocular Pressure Variation and Sex-Specific Effects. , 2020, 61, 20.		7
286	Topical Treatment of Elevated Intraocular Pressure in Patients with Graves's™ Orbitopathy. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9331.	2.6	3
287	ROCK inhibitors beneficially alter the spatial configuration of TGFβ <sup>2</sup> -treated 3D organoids from a human trabecular meshwork (HTM). <i>Scientific Reports</i> , 2020, 10, 20292.	3.3	28
288	Medical management of pediatric glaucoma: lessons learned from randomized clinical trials. <i>Graefes' Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 1579-1586.	1.9	12
289	Prostaglandin F <sub>2</sub> agonist-induced suppression of 3T3-L1 cell adipogenesis affects spatial formation of extra-cellular matrix. <i>Scientific Reports</i> , 2020, 10, 7958.	3.3	47
290	Microneedle ocular patch: fabrication, characterization, and <i>ex-vivo</i> evaluation using pilocarpine as model drug. <i>Drug Development and Industrial Pharmacy</i> , 2020, 46, 1114-1122.	2.0	31
291	Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension. <i>American Journal of Ophthalmology</i> , 2020, 220, 53-63.	3.3	67
292	Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study. <i>Japanese Journal of Ophthalmology</i> , 2020, 64, 398-406.	1.9	36
293	Acupuncture for glaucoma. <i>The Cochrane Library</i> , 2020, 2, CD006030.	2.8	10
294	Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management. <i>Survey of Ophthalmology</i> , 2020, 65, 496-512.	4.0	64
295	A scoping review and network meta-analysis for efficacy and safety of glaucoma medication in Japanese patients. <i>Japanese Journal of Ophthalmology</i> , 2020, 64, 103-113.	1.9	8
296	The Sustained Release of Tafluprost with a Drug Delivery System Prevents the Axonal Injury-induced Loss of Retinal Ganglion Cells in Rats. <i>Current Eye Research</i> , 2020, 45, 1114-1123.	1.5	7
297	Intraocular Pressure Following Prerandomization Glaucoma Medication Washout in the HORIZON and COMPASS Trials. <i>American Journal of Ophthalmology</i> , 2020, 216, 110-120.	3.3	10
298	Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma. <i>Drug Development and Industrial Pharmacy</i> , 2020, 46, 806-813.	2.0	33
299	Primary Open-Angle Glaucoma Preferred Practice Pattern®. <i>Ophthalmology</i> , 2021, 128, P71-P150.	5.2	144
300	Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern®. <i>Ophthalmology</i> , 2021, 128, P151-P192.	5.2	26
301	Glaucoma: Management and Future Perspectives for Nanotechnology-Based Treatment Modalities. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 158, 105648.	4.0	22

#	ARTICLE	IF	CITATIONS
302	Surgery for glaucoma in modern corneal graft procedures. <i>Survey of Ophthalmology</i> , 2021, 66, 276-289.	4.0	17
303	Management of open-angle glaucoma by primary eye-care practitioners: toward a personalised medicine approach. <i>Australasian journal of optometry, The</i> , 2021, 104, 367-384.	1.3	18
304	An Intraocular Pressure Measurement Technique Based on Acoustic Radiation Force Using an Ultrasound Transducer: A Feasibility Study. <i>Sensors</i> , 2021, 21, 1857.	3.8	0
305	Efficacy of the XEN-Implant in Glaucoma and a Meta-Analysis of the Literature. <i>Journal of Clinical Medicine</i> , 2021, 10, 1118.	2.4	18
306	Intraocular Pressure Reactivity to Social Stressors. <i>Journal of Psychophysiology</i> , 2021, 35, 89-101.	0.7	0
307	Prophylactic effect of brinzolamide-brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injections. <i>International Ophthalmology</i> , 2021, 41, 3191-3198.	1.4	2
308	Diverse effects of pan-ROCK and ROCK2 inhibitors on 2 D and 3D cultured human trabecular meshwork (HTM) cells treated with TGF $\beta$ 2. <i>Scientific Reports</i> , 2021, 11, 15286.	3.3	14
309	ROCK inhibitors modulate the physical properties and adipogenesis of 3D spheroids of human orbital fibroblasts in different manners. <i>FASEB BioAdvances</i> , 2021, 3, 866-872.	2.4	7
310	Periocular invasive melanoma manifestation in a patient using bimatoprost: case report and literature review. <i>Orbit</i> , 2023, 42, 73-80.	0.8	2
311	Screening of the Drug-Induced Effects of Prostaglandin EP2 and FP Agonists on 3D Cultures of Dexamethasone-Treated Human Trabecular Meshwork Cells. <i>Biomedicines</i> , 2021, 9, 930.	3.2	12
312	Fine Particulate Matter and Age-Related Eye Disease: The Canadian Longitudinal Study on Aging. , 2021, 62, 7.		23
313	Aspects of Tertiary Prevention in Patients with Primary Open Angle Glaucoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 830.	2.5	11
314	Dealing with pediatric glaucoma: from medical to surgical management—a narrative review. <i>Annals of Eye Science</i> , 0, 6, 25-25.	2.1	0
315	Cataract extraction and intraocular pressure-lowering agents delivery: A nationwide French study between 2005 and 2017. <i>European Journal of Ophthalmology</i> , 2022, 32, 2201-2210.	1.3	1
316	Establishment of appropriate glaucoma models using dexamethasone or TGF $\beta$ 2 treated three-dimension (3D) cultured human trabecular meshwork (HTM) cells. <i>Scientific Reports</i> , 2021, 11, 19369.	3.3	19
317	Effectiveness and Safety Verification of Brinzolamide Combination Therapy on Primary Open-angle Glaucoma or Ocular Hypertension: A Systematic Review and Meta-analysis Study. <i>Korean Journal of Clinical Pharmacy</i> , 2021, 31, 205-215.	0.3	0
318	Choosing Adjunctive Glaucoma Therapy. , 2010, , 629-641.		1
319	Monitoring retinal responses to acute intraocular pressure elevation in rats with visible light optical coherence tomography. <i>Neurophotonics</i> , 2019, 6, 1.	3.3	14

#	ARTICLE	IF	CITATIONS
320	Novel therapies for open-angle glaucoma. F1000prime Reports, 2014, 6, 102.	5.9	16
321	Efficacy and Tolerability of the Fixed Combinations Latanoprost/Timolol versus Dorzolamide/Timolol in Patients with Elevated Intraocular Pressure: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2013, 8, e83606.	2.5	6
322	The Prevalence and Incidence of Glaucoma in Denmark in a Fifteen Year Period: A Nationwide Study. PLoS ONE, 2015, 10, e0132048.	2.5	55
323	Screening, Diagnosis, and Management of Open Angle Glaucoma. Canadian Journal of Optometry, 2017, 79, 5-71.	0.0	6
326	Prostaglandin analogues: past, present, and future. Ophthalmology Journal, 2017, 10, 40-52.	0.2	13
327	Strategies to Reduce Oxidative Stress in Glaucoma Patients. Current Neuropharmacology, 2018, 16, 903-918.	2.9	55
328	Anterior Segment Optical Coherence Tomography Analysis of Iris Morphometric Changes Induced by Prostaglandin Analogues Treatment in Patients with Primary Open Angle Glaucoma or Ocular Hypertension. Open Ophthalmology Journal, 2018, 12, 110-120.	0.2	2
329	Fixed combinations of glaucoma medications. Srpski Arhiv Za Celokupno Lekarstvo, 2015, 143, 626-631.	0.2	6
330	Medical therapy for glaucoma. Basic and Clinical Dermatology, 2007, , 221-238.	0.1	1
331	The Medical and Surgical Treatment of Glaucoma. Deutsches A&#x0308;rztblatt International, 2009, 106, 597-605; quiz 606.	0.9	34
332	Selective Laser Trabeculoplasty: A Clinical Review. Journal of Current Glaucoma Practice, 2013, 7, 58-65.	0.5	11
333	A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension. Expert Opinion on Drug Safety, 2022, 21, 525-539.	2.4	7
334	The Intraocular Pressure Lowering Effect of a Dual Kinase Inhibitor (ITRI-E-(S)4046) in Ocular Hypertensive Animal Models. , 2021, 62, 12.		3
335	Laser surgery in the treatment of glaucoma. Basic and Clinical Dermatology, 2007, , 239-259.	0.1	0
337	Pressure Lowering Medications. , 0, , .		0
338	Pressure lowering effect of fixed combination and unfixed- combination of latanoprost and timolol in Asian population. Clinical Medicine Research, 2012, 1, 7.	0.1	1
339	Tolerancia y Efectividad de los AnÃ¡logos de Prostaglandinas en Pacientes Glaucomatosos. Highlights of Ophthalmology, 2013, 41, 22-26.	0.0	0
340	Tolerance and Effectivity of Prostaglandin Analogues in Glaucoma Patients. Highlights of Ophthalmology, 2013, 41, 19-22.	0.0	0

#	ARTICLE	IF	CITATIONS
341	Medications Used to Treat Glaucoma. , 2014, , 417-477.		0
342	Ophthalmika. , 2016, , 621-641.		0
343	Comparative Effect of Latanoprost/Timolol Fixed Combination and Unfixed Combination in Patients with Ocular Hypertension Attending Irrua Specialist Teaching Hospital, Irrua, Nigeria. IOSR Journal of Dental and Medical Sciences, 2016, 15, 62-65.	0.0	0
344	Ophthalmika. , 2017, , 641-661.		0
346	Ocular effect of preservative free and bak containing Travoprost - a tertiary care hospital based study. International Journal of Pharma and Bio Sciences, 2017, 8, .	0.1	2
347	Pharmacodynamic approach for proving equivalence of two opthalmic solutions containing Brimonidine Tartarate 0.2% in healthy volunteers. Hospital Pharmacology, 2018, 5, 581-589.	0.3	0
348	Ophthalmika. , 2018, , 693-714.		0
349	Ophthalmika. , 2019, , 877-902.		0
351	The comparison of pupil diameters in light and dark after 0.15% brimonidine drops in eyes with and without pseudoexfoliation. Beyoglu Eye Journal, 2020, 5, 209-213.	0.2	2
352	Ophthalmika. , 2020, , 733-758.		0
353	Treatment of glaucoma among elderly patients in Sofia. Romanian Journal of Ophthalmology, 2020, 64, 404-409.	0.5	0
354	Once-daily Preservative-free Topical Anti-glaucomatous Monotherapy â€œ A Better Approach?. European Ophthalmic Review, 2020, 14, 21.	0.3	0
355	Carbonic Anhydrase Inhibitors in Ophthalmology: Glaucoma and Macular Oedema. Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques, 2021, , 79-102.	0.6	1
356	Topical Prostaglandin Analogues with and without Preservatives on Tear Film Stability in the Long-Term Treatment of Glaucoma. Journal of Evidence Based Medicine and Healthcare, 2020, 7, 823-826.	0.0	0
357	Anti-glaucoma agents-induced pseudodendritic keratitis presumed to be herpetic simplex keratitis: a clinical case series. Scientific Reports, 2021, 11, 21443.	3.3	7
358	Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clinical Ophthalmology, 2008, 2, 897-905.	1.8	34
359	First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost. Clinical Ophthalmology, 2007, 1, 225-32.	1.8	5
360	Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany. International Journal of Ophthalmology, 2013, 6, 155-9.	1.1	9

#	ARTICLE	IF	CITATIONS
361	Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells. <i>Journal of Biochemical and Pharmacological Research</i> , 2014, 2, 175-184.	1.7	5
362	Beneficial Extracardiac Effects of Cardiovascular Medications. <i>Current Cardiology Reviews</i> , 2022, 18, .	1.5	3
363	The prophylactic effect of betaxolol 0.5% versus brimonidine 0.2% on IOP elevation after Nd:YAG laser posterior capsulotomy. <i>Australasian journal of optometry</i> , The, 2021, , 1-4.	1.3	0
364	The Effect of Intraocular Pressure-Lowering Medication on Metastatic Uveal Melanomas. <i>Cancers</i> , 2021, 13, 5657.	3.7	0
365	<i>Ophthalmika</i> , , 2021, , 639-666.		0
367	Comparison of the Drug-Induced Efficacies between Omidenepag Isopropyl, an EP2 Agonist and PGF <sub>2</sub> ± toward TGF-β <sub>2</sub> -Modulated Human Trabecular Meshwork (HTM) Cells. <i>Journal of Clinical Medicine</i> , 2022, 11, 1652.	2.4	1
368	Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2022, 38, 240-251.	1.4	5
369	Bimatoprost-Loaded Silica Shellâ€‘Coated Nanoparticles-Laden Soft Contact Lenses to Manage Glaucoma: In Vitro and In Vivo Studies. <i>AAPS PharmSciTech</i> , 2022, 23, 33.	3.3	1
371	Unmet needs in glaucoma therapy: The potential role of hydrogen sulfide and its delivery strategies. <i>Journal of Controlled Release</i> , 2022, 347, 256-269.	9.9	11
373	Human Trabecular Meshwork (HTM) Cells Treated with TGF-β <sub>2</sub> or Dexamethasone Respond to Compression Stress in Different Manners. <i>Biomedicines</i> , 2022, 10, 1338.	3.2	10
374	Efficacy and Safety of Micropulse Transscleral Cyclophotocoagulation. <i>Journal of Clinical Medicine</i> , 2022, 11, 3447.	2.4	5
375	Brimonidine Modulates the ROCK1 Signaling Effects on Adipogenic Differentiation in 2D and 3D 3T3-L1 Cells. <i>Bioengineering</i> , 2022, 9, 327.	3.5	3
376	Emerging drugs for the treatment of glaucoma: a review of phase II & III trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 321-331.	2.4	3
377	Clinical Practice Management of Primary Open-Angle Glaucoma in the United States: An Analysis of Real-World Evidence. <i>Patient Preference and Adherence</i> , 0, Volume 16, 2213-2227.	1.8	3
378	Addition of ROCK Inhibitors Alleviates Prostaglandin-Induced Inhibition of Adipogenesis in 3T3L-1 Spheroids. <i>Bioengineering</i> , 2022, 9, 702.	3.5	2
379	Inverse Association of APOE ε <sub>4</sub> and Glaucoma Modified by Systemic Hypertension: The Canadian Longitudinal Study on Aging., 2022, 63, 9.		2
380	Effect of Topical Prostaglandin Analogue Therapy on Central Corneal Thickness: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 44.	2.4	2
381	<i>Augenerkrankungen</i> , , 2022, , 569-598.		0

#	ARTICLE	IF	CITATIONS
382	Carbonic anhydrase inhibitors for the treatment of glaucoma. , 2023, , .		0
383	TGF- $\beta$ -3 Induces Different Effects from TGF- $\beta$ -1 and -2 on Cellular Metabolism and the Spatial Properties of the Human Trabecular Meshwork Cells. International Journal of Molecular Sciences, 2023, 24, 4181.	4.1	3
384	Prostaglandin analogs in ophthalmology. Indian Journal of Ophthalmology, 2023, 71, 1768-1776.	1.1	2
385	Simultaneous Effects of a Selective EP2 Agonist, Omidenepag, and a Rho-Associated Coiled-Coil Containing Protein Kinase Inhibitor, Ripasudil, on Human Orbital Fibroblasts. Journal of Ocular Pharmacology and Therapeutics, 0, , .	1.4	0
386	How latanoprost changed glaucoma management. Acta Ophthalmologica, 2024, 102, .	1.1	1
387	Alcohol Consumption, Genetic Risk, and Intraocular Pressure and Glaucoma: The Canadian Longitudinal Study on Aging. , 2023, 64, 3.		0
388	Prostanoid FP and EP2 Receptor Agonists Induce Epithelial and Subepithelial Fibrogenetic Changes in Human Conjunctival Fibroblasts in Different Manners. Journal of Ocular Pharmacology and Therapeutics, 2023, 39, 404-414.	1.4	0
389	Stable Gastric Pentadecapeptide BPC 157â€”Possible Novel Therapy of Glaucoma and Other Ocular Conditions. Pharmaceuticals, 2023, 16, 1052.	3.8	2
390	Pharmacotherapy of glaucoma in terms of evidence-based medicine. Kachestvennaya Klinicheskaya Praktika, 2023, , 44-54.	0.5	0
391	Effect of Selective Laser Trabeculoplasty in Ocular Hypertension. , 0, , .		0
392	Dementia and glaucoma: Results from a Nationwide French Study between 2006 and 2018. Acta Ophthalmologica, 0, , .	1.1	0
393	Glaucoma Patients Have a Lower Abundance of Butyrate-Producing Taxa in the Gut. , 2024, 65, 7.		0
394	Chemical Insights into Topical Agents in Intraocular Pressure Management: From Glaucoma Etiopathology to Therapeutic Approaches. Pharmaceutics, 2024, 16, 274.	4.5	0
395	Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3). American Journal of Ophthalmology, 2024, 263, 23-34.	3.3	0
396	Augenerkrankungen. , 2023, , 607-627.		0
397	Differential Effects of Benzalkonium Chloride on Human Trabecular Meshwork Cells Not Treated or Treated with Transforming Growth Factor- $\beta$ 2 or Dexamethasone. Journal of Ocular Pharmacology and Therapeutics, 2024, 40, 189-196.	1.4	0
398	Efficacy and Safety of Rho Kinase Inhibitors vs. Beta-Blockers in Primary Open-Angle Glaucoma: A Systematic Review with Meta-Analysis. Journal of Clinical Medicine, 2024, 13, 1747.	2.4	0
399	Epidemiological, Clinical, Therapeutic and Evolutive Profile of Primary Open-Angle Glaucoma in a Cameroonian Population. Open Journal of Ophthalmology, 2024, 14, 93-102.	0.3	0